Esketamine

The Postpartum Depression Market Size in the 7MM was estimated to be USD 138.75 Million in 2017 and is expected to grow further with rise in PPD prevalence and immense opportunities with only a single marketed therapy available. Depression is one of the most common complications of pregnancy. During or after p...

The hallucinogenic party drug, ketamine has passed the final problem for going into the clinical stage as an antidepressant. The US Food and Drug Administration (FDA), an independent advisory committee, supported in favour of commending a compound known as esketamine, used for treating depression. If the FDA giv...